Department of Clinical Laboratory Medicine, Juntendo University Faculty of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo, Japan.
J Atheroscler Thromb. 2010 Jul 30;17(7):722-9. doi: 10.5551/jat.3632. Epub 2010 Jun 2.
Hypercholesterolemic patients with inflammation are at high risk for cardiovascular events. Statins exert anti-inflammatory action independent of their cholesterol-lowering action. This study sought to clarify whether statin therapy reduces inflammatory markers in hypercholesterolemic patients and to determine factors that predict the reduction in these markers.
Fasting concentrations of lipoproteins and inflammatory markers were measured in 54 hypercholesterolemic patients, and age- and gender-matched healthy volunteers. Carotid atherosclerosis was determined by ultrasonography. Blood samples were also analyzed in hypercholesterolemic patients after 4 weeks of statin therapy.
The high-sensitivity C-reactive protein (hs-CRP) and serum amyloid A (SAA) protein concentrations did not differ between the two groups. Statin therapy reduced the median hs-CRP and SAA concentrations in hypercholesterolemic patients from 0.75 to 0.60 mg/L (p=0.05), and from 3.95 to 3.20 microg/mL (p=0.20), respectively. These reductions were significant for both markers, but only in subgroups with high baseline concentrations. Statins exhibited different results for hs-CRP and SAA in the presence of carotid atherosclerosis.
Statin therapy reduces inflammatory markers in hypercholesterolemic patients, and this anti-inflammatory action is limited to patients whose inflammatory markers are elevated at baseline.
伴有炎症的高胆固醇血症患者发生心血管事件的风险较高。他汀类药物具有独立于其降脂作用的抗炎作用。本研究旨在阐明他汀类药物治疗是否能降低高胆固醇血症患者的炎症标志物，并确定预测这些标志物降低的因素。
测量了 54 例高胆固醇血症患者和年龄及性别匹配的健康志愿者的空腹脂蛋白和炎症标志物浓度。通过超声检查确定颈动脉粥样硬化。在他汀类药物治疗 4 周后，还对高胆固醇血症患者的血液样本进行了分析。
两组间高敏 C 反应蛋白（hs-CRP）和血清淀粉样蛋白 A（SAA）蛋白浓度无差异。他汀类药物治疗使高胆固醇血症患者的 hs-CRP 中位数从 0.75 降至 0.60mg/L（p=0.05），SAA 浓度从 3.95 降至 3.20μg/mL（p=0.20）。这两种标志物的降低均有统计学意义，但仅在基线浓度较高的亚组中如此。他汀类药物在存在颈动脉粥样硬化的情况下对 hs-CRP 和 SAA 产生了不同的结果。
他汀类药物治疗可降低高胆固醇血症患者的炎症标志物，这种抗炎作用仅限于基线炎症标志物升高的患者。
